Halozyme Therapeutics Inc. (NASDAQ: HALO)’s stock price has plunge by 7.03relation to previous closing price of 51.94. Nevertheless, the company has seen a 0.60% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2024-08-06 that Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Tram Bui – Vice President of Investor Relations and Corporate Communications Helen Torley – President and Chief Executive Officer Nicole LaBrosse – Chief Financial Officer Conference Call Participants Jason Butler – Citizens JMP Cerena Chen – Wells Fargo Jessica Fye – JP Morgan Michael DiFiore – Evercore ISI Mitchell Kapoor – H.C. Wainwright Brendan Smith – TD Cowen Vikram Purohit – Morgan Stanley Joseph Catanzaro – Piper Sandler Operator Good afternoon.
Is It Worth Investing in Halozyme Therapeutics Inc. (NASDAQ: HALO) Right Now?
The price-to-earnings ratio for Halozyme Therapeutics Inc. (NASDAQ: HALO) is above average at 21.55x, Company’s 36-month beta value is 1.27.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for HALO is 125.88M, and currently, short sellers hold a 6.92% ratio of that floaft. The average trading volume of HALO on August 07, 2024 was 1.31M shares.
HALO’s Market Performance
HALO stock saw an increase of 0.60% in the past week, with a monthly gain of 5.13% and a quarterly increase of 34.90%. The volatility ratio for the week is 3.34%, and the volatility levels for the last 30 days are 2.97% for Halozyme Therapeutics Inc. (HALO). The simple moving average for the past 20 days is 2.34% for HALO’s stock, with a 33.35% simple moving average for the past 200 days.
Analysts’ Opinion of HALO
Many brokerage firms have already submitted their reports for HALO stocks, with Piper Sandler repeating the rating for HALO by listing it as a “Neutral.” The predicted price for HALO in the upcoming period, according to Piper Sandler is $51 based on the research report published on June 07, 2024 of the current year 2024.
TD Cowen, on the other hand, stated in their research note that they expect to see HALO reach a price target of $54. The rating they have provided for HALO stocks is “Outperform” according to the report published on February 29th, 2024.
H.C. Wainwright gave a rating of “Buy” to HALO, setting the target price at $61 in the report published on July 24th of the previous year.
HALO Trading at 8.32% from the 50-Day Moving Average
After a stumble in the market that brought HALO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.62% of loss for the given period.
Volatility was left at 2.97%, however, over the last 30 days, the volatility rate increased by 3.34%, as shares surge +5.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +27.00% upper at present.
During the last 5 trading sessions, HALO rose by +0.71%, which changed the moving average for the period of 200-days by +55.45% in comparison to the 20-day moving average, which settled at $54.45. In addition, Halozyme Therapeutics Inc. saw 50.41% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HALO starting from LaBarre Michael J., who sale 10,000 shares at the price of $55.12 back on Jul 24 ’24. After this action, LaBarre Michael J. now owns 168,176 shares of Halozyme Therapeutics Inc., valued at $551,150 using the latest closing price.
LaBarre Michael J., the SVP, CHIEF TECHNICAL OFFICER of Halozyme Therapeutics Inc., sale 10,000 shares at $54.89 during a trade that took place back on Jul 23 ’24, which means that LaBarre Michael J. is holding 168,176 shares at $548,873 based on the most recent closing price.
Stock Fundamentals for HALO
Current profitability levels for the company are sitting at:
- 0.46 for the present operating margin
- 0.78 for the gross margin
The net margin for Halozyme Therapeutics Inc. stands at 0.39. The total capital return value is set at 0.22. Equity return is now at value 153.16, with 17.85 for asset returns.
Based on Halozyme Therapeutics Inc. (HALO), the company’s capital structure generated 0.84 points at debt to capital in total, while cash flow to debt ratio is standing at 0.29. The debt to equity ratio resting at 5.19. The interest coverage ratio of the stock is 41.42.
Currently, EBITDA for the company is 422.43 million with net debt to EBITDA at 2.84. When we switch over and look at the enterprise to sales, we see a ratio of 9.57. The receivables turnover for the company is 4.07for trailing twelve months and the total asset turnover is 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.41.
Conclusion
In a nutshell, Halozyme Therapeutics Inc. (HALO) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
